Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Novartis Capital Markets Day, focus R&D December 2, 2021 Virtual Meet Novartis Management May 23-24, 2022 In-person Key R&D assets include: Life-cycle management: Cosentyx LEQVIO KISQALI Power within your reach ribociclib Mid-stage: Pelacarsen, iptacopan, ligelizumab, remibrutinib, canakinumab, 177Lu-PSMA-617, asciminib Early-stage: including technology platforms 45 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation